Determination of the maximal carcinoma/normal skin ratio after HpD or m-THPC administration in Hairless mice (SKH-1) by fluorescence spectroscopy
- 1 February 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 11 (2) , 85-91
- https://doi.org/10.1097/00001813-200002000-00004
Abstract
The two major steps in our study on the treatment of skin carcinomas by photochemotherapy (PCT) were the development of a skin tumor model in Hairless mice by a chemical carcinogenesis and the use of fluorescence spectroscopy, a semi-quantitative and non-invasive method, in order to determine the time after i.p. injection of photosensitizer when the tumor/normal skin ratio was the highest. A three-step carcinogenesis protocol provided mice bearing carcinomas and these were used to determine the tumor/normal skin ratios of two photosensitizers by fluorescence spectroscopy. Hematoporphyrin derivative (HpD) (5 mg/kg body weight) and m-tetra(hydroxyphenyl) chlorine (m-THPC) (0.3 mg/kg body weight) were injected i.p., and fluorescence was measured at 1, 4, 8, 12, 24, 48, 72 and 96 h after injection. The best carcinoma/normal skin ratio would be 3.2±1.4 for HpD and 2.7±2.1 for m-THPC, respectively. The delays required to reach these ratios were 72 h for HpD and 24 h for m-THPC. These results have to be considered with caution due to the high SEs and they must be confirmed by organic extraction. Photodynamic therapy with the same doses of HpD and m-THPC used in this pharmacokinetic study has to be carried out in order to compare the toxicities of the two photosensitizers and to determine which one is the best for this type of tumor.Keywords
This publication has 24 references indexed in Scilit:
- The kinetics of protoporphyrin fluorescence during ALA-PDT in human malignant skin tumorsCancer Letters, 1997
- Photodynamic Therapy for Early Squamous Cell Carcinomas of the Esophagus, Bronchi, and Mouth With m-Tetra(Hydroxyphenyl) ChlorinJAMA Otolaryngology–Head & Neck Surgery, 1997
- Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissuesCancer Letters, 1997
- Determination of the maximal tumor/normal skin ratio after HpD or m-THPC administration in hairless mouse (SKh-1) by fluorescence spectroscopy???a non-invasive methodAnti-Cancer Drugs, 1997
- Photodynamic Therapy as an Adjuvant Intraoperative Treatment of Recurrent Head and Neck CarcinomasJAMA Otolaryngology–Head & Neck Surgery, 1996
- Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopyLasers in Surgery and Medicine, 1996
- DISTRIBUTION OF TEMOPORFIN, A NEW PHOTOSENSITIZER FOR THE PHOTODYNAMIC THERAPY OF CANCER, IN A MURINE TUMOR MODELPhotochemistry and Photobiology, 1995
- Evaluation of a new photosensitizer, meso‐tetra‐hydroxyphenyl‐chlorin, for use in photodynamic therapy: A comparison of its photobiological properties with those of two other photosensitizersInternational Journal of Cancer, 1994
- Determination of 5,10,15,20‐tetra‐(m‐hydroxyphenyl) chlorin in tissues by high performance liquid chromatographyBiomedical Chromatography, 1993
- PHOTODYNAMIC THERAPY OF CHEMICALLY‐ AND ULTRAVIOLET B RADIATION‐INDUCED MURINE SKIN PAPILLOMAS BY CHLOROALUMINUM PHTHALOCYANINE TETRASULFONATEPhotochemistry and Photobiology, 1992